

## Technology Advisory Committee A Interests Register

**Topic: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer [ID3741]**

**Publication Date: 20/10/2021**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Wasat Mansoor	Clinical expert	Direct – financial	Previously received honoraria for attending an advisory board for MSD	N/A	16/12/2020	N/A	It was agreed that this declaration would not prevent them providing expert advice to the committee.
Dr Elizabeth Smyth	Clinical expert	Direct – financial	<p>Received financial remuneration and/or travel support from the following companies: Astellas, Astra Zeneca, BMS, Celgene, Everest Research, Five Prime, Gritstone, Merck, Roche, Servier and Zymeworks</p> <p>Chief investigator of a trial which is managed by Southampton CTU which has been funded by BMS</p> <p>Her institution receives funding (either directly or</p>	N/A	16/12/2020	N/A	It was agreed that this declaration would not prevent them providing expert advice to the committee.

		Direct – non-financial	<p>through contract research organisations) for trials on which she is principal investigator from Astellas, Astra Zeneca, Basilea, Daiichi Sankyo, MSD and Roche.</p> <p>I am the co-chair of the EORTC (European Organisation for Research and Treatment of Cancer) Gastric Cancer Taskforce</p>				
--	--	------------------------	--	--	--	--	--

## GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.